Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase NA 16Phase 3 9Phase 1/2 9Phase 4 7Phase 1 7Phase EARLY_PHASE1 4Phase 2/3 3

Status

Completed 6Recruiting 3Unknown 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 75Other hematologic neoplasm 32Lymphoid 27Genitourinary 27Gynecologic 25Thoracic 23Head & Neck 20Breast 17Plasma cell 9Dermatologic 9CNS 8Tumor-Agnostic 5Myeloid 5Endocrine 5Other 4Sarcoma 3Other solid neoplasm 3NET 3Classical hematology 3

Conditions

Venous Thromboembolism 1Urologic Neoplasms 1Urogenital Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Cancer Treatment-Induced Thrombocytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 1cedazuridine 1Rivaroxaban 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Classical hematology × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06456528 2026-01-12

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Recruiting
235 enrolled
Classical hematology

Cancer Treatment-Induced Thrombocytopenia

NCT05920343 2025-07-10

PREVENT-GU

Ottawa Hospital Research Institute

Phase 2/3 Recruiting
120 enrolled
Classical hematologyGenitourinary

Urogenital Neoplasms, Urologic Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡